VEGFA and diabetes mellitus: We extended this strategy to HRECs cultured in normal glucose (NG; 5 mM) conditions because anti-VEGF therapy is effective at restoring barrier integrity not only in patients with diabetes (PDR, DME), but also in patients whose blood glucose is not chronically elevated (nAMD) [12,13].